Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Review

Acute and chronic animal models for the evaluation of anti-diabetic agents

Authors: Suresh Kumar, Rajeshwar Singh, Neeru Vasudeva, Sunil Sharma

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Diabetes mellitus is a potentially morbid condition with high prevalence worldwide thus being a major medical concern. Experimental induction of diabetes mellitus in animal models is essential for the advancement of our knowledge and understanding of the various aspects of its pathogenesis and ultimately finding new therapies and cure. Experimental diabetes mellitus is generally induced in laboratory animals by several methods that include: chemical, surgical and genetic (immunological) manipulations. Most of the experiments in diabetes are carried out in rodents, although some studies are still performed in larger animals. The present review highlights the various methods of inducing diabetes in experimental animals in order to test the newer drugs for their anti-diabetic potential.
Literature
1.
King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21: 1414-1431. 10.2337/diacare.21.9.1414.PubMed
2.
Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997, 14 (5): 1-85.
3.
IDF Diabetes Atlas. 2009, International Diabetes Federation, 4
4.
Mohan V, Pradeepa R: Epidemiology of diabetes in different regions of India. Health Administrator. 2009, 22: 1-18.
5.
Rother KI: Diabetes treatment--bridging the divide". The New England Journal of Medicine. 2007, 356 (15): 1499-501. 10.1056/NEJMp078030.PubMedCentralPubMed
6.
Other types of diabetes. 2005, American Diabetes Association
7.
Handelsman Yehuda MD: A Doctor's Diagnosis: Prediabetes. Power of Prevention. 2009, 1 (2): 1.
8.
"Diseases: Johns Hopkins Autoimmune Disease Research Center". Retrieved 2007-09-23
9.
World Health Organisation. Department of Noncommunicable Disease Surveillance: 1999, "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications"
10.
Potenza MA, Nacci C, Gagliardi S, Montagnani M: Cardiovascular complications in diabetes: lessons from animal models. Curr Med Chem. 2011, 18: 1806-19. 10.2174/092986711795496755.PubMed
11.
Rastellini C, Shapiro R, Corry R, Fung JJ, Starzl TE, Rao AS: An attempt to reverse diabetes by delayed islet cell transplantation in Humans. Transplantation. 1997, 29: 2238-2239.
12.
Rydgren T, Vaarala O, Sandler S: Simvastatin protects against multiple low dose streptozotocin in-duced type 1 diabetes in CD-1 mice and recurrence of the disease in nonobese diabetic mice. J Pharma-col Expt Ther. 2007, 23: 180-185.
13.
Balamurugan AN, Miyamoto M, Wang W, Inoue K, Tabata Y: Streptozotocin (STZ) used to in-duce diabetes in animal models. J Ethnopharm. 2003, 26: 102-103.
14.
Hayashi K, Kojima R, Ito M: Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharmaceut Bull. 2006, 29: 1110-1119. 10.1248/bpb.29.1110.
15.
Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001, 50: 537-46.PubMed
16.
Takeshita F, Kodama M, Yamamoto H, Ikarashi Y, Ueda S, Teratani T, Yamamoto Y, Tamatani T, Kanegasaki S, Ochiya T, Quinn G: Streptozotocin-induced partial beta cell depletion in nude mice without hyperglycaemia induces pancreatic morphogenesis in transplanted embryonic stem cells. Diabetologia. 2006, 49: 2948-58. 10.1007/s00125-006-0432-z.PubMed
17.
Weiss RB: Streptozotocin: A review of its pharmacology, efficacy and toxicity. Canc Treat Rep. 1982, 66: 427-438.
18.
Brosky G, Logothetopoulos J: Streptozotocin diabetes in the mouse and guinea pig. Diabetes. 1969, 8: 606-611.
19.
Ito M: New model of progressive non-insulin-dependent diabetes mellitus in mice induced by Streptozotocin. Biol Pharmaceut Bull. 1999, 22: 988-989. 10.1248/bpb.22.988.
20.
Ikebukuro K, Adachi Y, Yamada Y, Fujimoto S, Seino Y, Oyaizu H: Treatment of Streptozotocin-induced diabetes mellitus by transplantation of islet cells Plus bone Marrow cells via portal vein in rats. Transplantation. 2002, 73: 512-518. 10.1097/00007890-200202270-00004.PubMed
21.
Smith SB, Prior RL, Mersmann HJ: Interrelationship between insulin and lipid metabolism in normal and alloxan-diabetic cattle. J Nutr. 1983, 113: 1002-1015.PubMed
22.
Viana GS, Medeiros AC, Lacerda AM, Leal LK, Vale TG, Matos FJ: Hypoglycemic and anti-lipidemic effects of the aqueous extract of Cissus si-cyoides. BMC Pharmacol. 2004, 8: 4-9.
23.
Szkudelski T: The mechanism of alloxan and streptozotocin action β cells of the rat pancreas. Physiology Res. 2001, 50: 536-546.
24.
Bartosikova L, Nieces J, Succhy V, Kubinov R, Vesa-la D, Benes L: Monitoring of antoxidative effect of morine in alloxan-induced diabetes mellitus in the laboratory rat. Acta Vet Bull. 2003, 72: 191-200. 10.2754/avb200372020191.
25.
Takasu N, Asawa T, Komiya I, Nagasawa Y, Yama-da T: Alloxan induced DNA strand breaks in pancreatic islets. Journal of Biochemistry. 1991, 266: 2112-2114.
26.
Masiello P: Animal models of type11 diabetes with reduced pancreatic β-cell mass. The interna-tional Journal of Biochemistry and Cell Biology. 2006, 38: 873-893. 10.1016/j.biocel.2005.09.007.
27.
Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002, 48: 436-472.PubMed
28.
Nathan DM, Turgeon H, Regans S: Relationship between Glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007, 50: 2239-2244. 10.1007/s00125-007-0803-0.PubMed
29.
Barrett-Connor E, Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol. 1983, 118: 489-96.PubMed
30.
Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program Diabetes. 1987, 36: 689-92.PubMed
31.
Harris Ml, Entmacher PS: Mortality from diabetes. Edited by: Harris Ml, Hamman RF. 1985, Diabetes in America. U.S. Government Printing Office, NIH, 1-48.
32.
Wetterhall SF, Olson DR, DeStefano F, Stevenson JM, Ford ES, German RR: Trends in diabetes and diabetic complications, 1980-1987. Diabetes Care. 1992, 15: 960-967. 10.2337/diacare.15.8.960.PubMed
33.
Vogel HG, Vogel WH: Drug discovery and evaluation: pharmacological assays. 2002, Springer-Verlag Berlin Heidelberg, New York, 948-1051. Herling AW: Antidiabetic activity
34.
Banting FG, Best CH: The internal secretion of the pancreas. J Lab Clin Med. 1922, 7: 251-266.
35.
Foa PP: Pankreatektomie. Dörzbach Handbook of experimental Pharmacology. 1971, Insulin, Springer-Verlag, Berlin Heidelberg New York, 32/1: 146-158.
36.
Sirek A: Pancreatectomy and diabetes. Handbook of Diabetes mellitus, Pathophysiology and clinical Considerations. Edited by: Pfeiffer EF. 1968, Lehmanns Verlag, München, I: 727-743.
37.
Frerichs H, Creutzfeldt W: Der experimentelle chemische Diabetes. Handbook of Experimental Pharmacology. Edited by: Dörzbach E. 1971, Insulin, Springer-Verlag, Berlin Heidelberg New York, 32/1: 159-202.
38.
Tasaka Y, Inoue Y, Matsumoto H, Hirata Y: Changes in plasma glucagon, pancreatic polypeptide and insulin during development of alloxan diabetes mellitus in dog. Endocrinol Japon. 1988, 35: 399-40. 10.1507/endocrj1954.35.399.
39.
Baily CC, Baily OT: Production of diabetes mellitus inrabbits with alloxan. A preliminary report. J Am Med. 1943, 122: 1165-1166.
40.
Goldner MG, Gomori G: Studies on the mechanism of alloxan diabetes. Endocrinology. 1944, 35: 241-248. 10.1210/endo-35-4-241.
41.
Frerichs H, Creutzfeldt W: Diabetes durch Beta-Zytotoxine. Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Edited by: Pfeiffer EF. 1968, LehmannsVerlag, München, I: 811-840.
42.
Maske H, Weinges K: Untersuchungen über das Verhalten der Meerschweinchen gegenüber verschiedenen diabetogenen Noxen. Alloxan und Dithizon. Naunyn-Schmiedeberg's Arch exper Path Pharmakol. 1957, 230: 406-420.
43.
Bänder A, Pfaff W, Schmidt FH, Stork H, Schröder HG: Zur Pharmakologie von HB 419, einem neuen, starwirksamenoralen Antidiabeticum. Arzneim Forsch Drug Res. 1969, 19: 1363-1372.
44.
Katsumata K, Katsumata Y, Ozawa T, Katsumata JR: Potentiating effect of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats. Horm Metab Res. 1993, 25: 125-126. 10.1055/s-2007-1002058.PubMed
45.
Geisen K: Special pharmacology of the new sulfonylurea glimepiride. Arzneim Forsch Drug Res. 1988, 38: 1120-1130.
46.
Kodoma T, Iwase M, Nunoi K, Maki Y, Yoshinari M, Fujishima M: A new diabetes model induced by neonatal alloxan treatment in rats. Diab Res Clin Pract. 1993, 20: 183-189. 10.1016/0168-8227(93)90076-H.
47.
Rakieten N, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963, 29: 91-102.
48.
Masutani M, Suzuki H, Kamada N, Watanabe M, Ueda O, Jishage K-I, Watanabe T, Sugimoto T, Nakagama H, Sugimura T: Poly(ADP-ribose)polymerase gene disruptionconferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci. 1998, 2301-2304. 96
49.
Cotes PM, Reid E, Young FG: Diabetogenic action of pure anterior pituitary growth hormone. Nature. 1949, 164: 209-211. 10.1038/164209a0.PubMed
50.
Young FG: Growth and diabetes in normal animals treated with pituitary (anterior lobe) diabetogenic extract. Biochem J. 1941, 39: 515-536.
51.
Ingle DJ: The production of glycosuria in the normal rat by means of 17-hydroxy-11-dehydrocorticosterone. Endocrinology. 1941, 29: 649-652.
52.
Abelove WA, Paschkis KE: Comparison of the diabetogenic action of cortisone and growth hormone in different species. Endocrinology. 1994, 55: 637-654.
53.
Ingle DJ, Li CH, Evans HM: The effect of adrenocorticotropic hormone on the urinary excretion of sodium, chloride, potassium, nitrogen and glucose in normal rats. Endocrinology. 1946, 39: 32-39. 10.1210/endo-39-1-32.PubMed
54.
Craighead J: Current views on the etiology of insulin-dependent diabetes mellitus. New Engl J Med. 1978, 299: 1439-1445. 10.1056/NEJM197812282992605.PubMed
55.
Vialettes B, Baume D, Charpin C, De Maeyer-Guignard J, Vague P: Assessment of viral and immune factors in EMC virus- induced diabetes: effects of cyclosporin A and interferon. J Lab Clin Immunol. 1983, 10: 35-40.
56.
Hansen WA, Christie MR, Kahn R, Norgard A, Abel I, Petersen AM, Jorgensen DW, Baekkeskov S, Nielsen JH, Lernmark A, Egeberg J, Richter-Olesen H, Grainger T, Kristensen JK, Brynitz S, Bilde T: Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res. 1989, 10: 53-57.PubMed
57.
Heydrick SJ, Gautier N, Olichon-Berte C, Van Obberghen E, Le Marchand Brustel Y: Early alteration of insulin stimulation of PI 3-kinase in muscle and adipocyte from gold thioglucose obese mice. Am J Physiol Endocrinol Metab. 1995, 268: 604-612.
58.
Sartin JL, Lamperti AA, Kemppainen RJ: Alterations in insulin and glucagon secretion by monosodium glutamate lesions of the hypothalamic arcuate nucleus. Endocr Res. 1985, 11: 145-155.PubMed
59.
Goldberg ED, Eshchenko VA, Bovt VD: The diabetogenic and acidotropic effects of chelators. Exp Pathol. 1991, 42: 59-64. 10.1016/S0232-1513(11)80038-1.PubMed
60.
Wright PH: Experimental insulin-deficiency due to insulin antibodies. Handbook of Diabetes mellitus, Pathophysiology and Clinical Considerations. Edited by: Pfeiffer EF. 1968, Lehmanns Verlag, München, I: 841-865.
61.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JF: Positional cloning of the mouse obese gene and its human homologue. Nature. 1994, 372: 425-432. 10.1038/372425a0.PubMed
62.
Friedman JF, Halaas JL: Leptin and the regulation of body weight in mammals. Nature. 1998, 395: 763-770. 10.1038/27376.PubMed
63.
Ellerman K, Wroblewski M, Rabinovitch A, Like A: Natural killer cell depletion and diabetes mellitus in the BB/Wor rat. Diabetologia. 1993, 36: 596-601. 10.1007/BF00404067.PubMed
64.
Hao L, Chan SM, Lafferty KJ: Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci. 1993, 969: 328-332.
65.
Klöting I, Vogt L: BB/O(TTAWA)K(ARLSBURG) rats:features of a subline of diabetes prone BB rats. Diabetes Res. 1991, 18: 79-87.PubMed
66.
Yagihashi S, Wada RI, Kamijo M, Nagai K: Peripheral neuropathy in the WBN/Kob rat with chronic pancreatitis and spontaneous diabetes. Lab Invest. 1993, 68: 296-307.PubMed
67.
Cohen AM, Teitelbaum A, Saliternik R: Genetics and diet as factors in the development of diabetes mellitus. Metabolism. 1972, 21: 235-240. 10.1016/0026-0495(72)90046-7.
68.
Velasquez MT, Kimmel PL, Michaelis OE: Animal models of spontaneous diabetic kidney disease. FASEB J. 1972, 4: 2850-2859.
69.
Begum N, Ragiola L: Altered regulation of insulin signaling components in adipocytes of insulin-resistant type II diabetic Goto-Kakizaki rats. Metabolisms. 1998, 47: 54-62. 10.1016/S0026-0495(98)90193-7.
70.
Zucker LM: Hereditary obesity in the rat associated with hyperlipidemia. Ann NY Acad Sci. 1965, 131: 447-458. 10.1111/j.1749-6632.1965.tb34810.x.PubMed
71.
Galante P, Maerker E, Scholz R, Rett K, Herberg L, Mosthaf L, Häring HU: Insulin-induced translocation of GLUT 4 in skeletal muscle of insulin-resistant Zucker rats. Diabetologia. 1994, 37: 3-9. 10.1007/BF00428770.PubMed
72.
Peterson RG, Shaw WN, Neel M-AN, Little LA, Eicheberg J: Zucker Diabetic Fatty rat as a model for non-insulindependent diabetes mellitus. ILAR News. 1990, 32: 16-19.
73.
Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocytes-β-cell relationships. Proc Natl Acad Sci. 1994, 91: 10878-10882. 10.1073/pnas.91.23.10878.PubMedCentralPubMed
74.
Velasquez MT, Kimmel PL, Michaelis OE: Animal models of spontaneous diabetic kidney disease. FASEB J. 1990, 4: 2850-2859.PubMed
75.
Ishida K, Mizuno A, Sano T, Shima K: Which is the primary etiologic event in Otsuka Long-Evans Tokushima fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus, insulin resistance, or impaired insulin secretion?. Metabolism. 1995, 44: 940-945. 10.1016/0026-0495(95)90249-X.PubMed
76.
Tarrés MC, Martínez SM, Liborio MM, Rabasa SL: Diabetes mellitus en una línea endocrinada de rata. Mendeliana. 1981, 5: 39-48.
77.
Dumm CLAG, Semino MC, Gagliardino JJ: Sequential changes in pancreatic islets of spontaneously diabetic rats. Pancreas. 1990, 5: 533-539. 10.1097/00006676-199009000-00007.
78.
Koletsky S: Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol. 1975, 80: 129-142.PubMedCentralPubMed
79.
Russell JC, Graham S, Hameed M: Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism. 1994, 43: 538-543. 10.1016/0026-0495(94)90192-9.PubMed
80.
Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Kaung HL, Ernsberger P: Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol Endocrinol Metab. 1997, 273: E1014-1023.
81.
Adamo M, Shemer J, Aridor M, Dixon J, Carswell N, Bhathena SJ, Michaelis OE, LeRoith D: Liver insulin receptor tyrosine kinase activity in a model of type II diabetes mellitus and obesity. J Nutr. 1989, 119: 484-489.PubMed
82.
Velasquez MT, Kimmel PL, Michaelis OE: Animal models of spontaneous diabetic kidney disease. FASEB J. 1990, 4: 2850-2859.PubMed
83.
Nakamura M, Yamada K: Studies on a diabetic (KK) strain of the mouse. Diabetologia. 1967, 3: 212-221. 10.1007/BF01222198.PubMed
84.
Iwatsuka H, Shino A, Suzouki Z: General survey of diabetic features of yellow KK mice. Endocrinol Japon. 1970, 17: 23-35. 10.1507/endocrj1954.17.23.
85.
Diani AR, Sawada GA, Zhang NY, Wyse BM, Connell CL, Vidmar TJ, Connell MA: The KKAy mouse: a model for the rapid development of glomerular capillary basement membrane thickening. Blood Vessels. 1987, 24: 297-303.PubMed
86.
Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM: Rapamycin prevents the onset of insulin dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol. 1992, 89: 174-178.PubMedCentralPubMed
87.
Nicoletti F, Di Marco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, Meroni PL: Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol. 1994, 24: 1843-1847. 10.1002/eji.1830240818.PubMed
88.
Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P: Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med. 1997, 186: 1663-1676. 10.1084/jem.186.10.1663.PubMedCentralPubMed
89.
Bleisch VR, Mayer J, Dickie MM: Familial diabetes mellitus in mice associated with insulin resistance, obesity and hyperplasia of the islands of Langerhans. Am J Pathol. 1952, 28: 369-385.PubMedCentralPubMed
90.
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weightreducing effects of the plasma protein encoded by the obesegene. Science. 1995, 269: 543-546. 10.1126/science.7624777.PubMed
91.
Herberg L, Coleman DL: Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism. 1977, 26: 59-99. 10.1016/0026-0495(77)90128-7.PubMed
92.
Tartaglia LA, Dembski M, Wenig X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J: Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995, 83: 1263-1271. 10.1016/0092-8674(95)90151-5.PubMed
93.
Like AA, Lavine RL, Poffenbarger PL, Chick WI: Studies on the diabetic mutant mouse. VI Evolution of glomerular lesions and associated proteinuria. Am J Pathol. 1972, 66: 193-224.PubMedCentralPubMed
94.
Friedman JF, Halaas JL: Leptin and the regulation of body weight in mammals. Nature. 1998, 395: 763-770. 10.1038/27376.PubMed
95.
Connelly DM, Taberner PV: Characterization of spontaneous diabetes obesity syndrome in mature CBA/Ca mice. Pharmacol Biochem Behav. 1989, 34: 255-259. 10.1016/0091-3057(89)90308-0.PubMed
96.
Jones E: Spontaneous hyperplasia of the pancreatic islets associated with glycosuria in hybrid mice. The structure and metabolism of pancreatic islets. Edited by: Brolin SE, Hellman B, Knutson H. 1964, Pergamon Press, Oxford, 189-191.
97.
Like AA, Jones EE: Studies on experimental diabetes in the Wellesley hybrid mouse. IV. Morphologic changes in islet tissue. Diabetologia. 1967, 3: 179-187. 10.1007/BF01222196.PubMed
98.
Meier H, Yerganian G: Spontaneous hereditary diabetes mellitus in the Chinese hamster (Cricetulus griseus). III. Maintenance of a diabetic hamster colony with the aid of hypoglycemictherapy. Diabetes. 1961, 10: 19-21.PubMed
99.
Strasser H: A breeding program for spontaneously diabetic experimental animals.: Psammomys obesus (sand rat) and Acomyscahirinus (spiny mouse). Lab Anim Care. 1968, 18: 328-338.PubMed
100.
Dubault J, Boulanger M, Espinal J, Marquie G, Petkov P, du Boistesselin R: Latent autoimmune diabetes mellitus in adult humans with non-insulin-dependent diabetes: Is Psammomys obesus a suitable animal model?. Acta Diabetol. 1995, 32: 92-94. 10.1007/BF00569564.
101.
Pictet R, Orci L, Gonet AE, Rouiller Ch, Renold AE: Ultrastructural studies of the hyperplastic islets of Langerhans of spiny mice (Acomys cahirinus) before and during the development of hyperglycemia. Diabetologia. 1967, 3: 188-211. 10.1007/BF01222197.PubMed
102.
Schmidt G, Martin AP, Stuhlman RA, Townsend JF, Lucas FV, Vorbeck ML: Evaluation of hepatic mitochondrial function in the spontaneously diabetic Mystromys albicaudatus. Lab Invest. 1974, 30: 451-457.PubMed
103.
Wise PH, Weir BJ, Hime JM, Forrest E: The diabetic syndrome in the Tuco-Tuco (Ctenomis talarum). Diabetologia. 1972, 8: 165-172. 10.1007/BF01212256.PubMed
104.
Howard CF: Basement membrane thickness in muscle capillaries of normal and spontaneously diabetic Macaca nigra. Diabetes. 1975, 24: 201-206. 10.2337/diabetes.24.2.201.PubMed
105.
Schaefer EM, Viard V, Morin J, Ferré P, Pénicaud L, Ramos P, Maika SD, Ellis L, Hammer RE: A new transgenic mouse model of chronic hyperglycemia. Diabetes. 1994, 43: 143-153. 10.2337/diabetes.43.1.143.PubMed
106.
Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, Brinster RL: Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell. 1987, 50: 435-443. 10.1016/0092-8674(87)90497-1.PubMed
107.
Aichele P, Hyburtz D, Ohashi POS, Odermatt B, Zinkernagel , Hengartner H, Pircher H: Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci. 1994, 91: 444-448. 10.1073/pnas.91.2.444.PubMedCentralPubMed
108.
Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell. 1991, 65: 319-331. 10.1016/0092-8674(91)90165-U.PubMed
109.
Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H: Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991, 65: 305-317. 10.1016/0092-8674(91)90164-T.PubMed
110.
Von Herrath MG, Dockter J, Oldstone MBA: How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic mouse model. Immunity. 1994, 1: 231-242. 10.1016/1074-7613(94)90101-5.PubMed
111.
Von Herrath MG, Holz A: Pathological changes in the islet milieu precede infiltration of islets and destruction in β-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM. J Autoimmun. 1997, 10: 231-238. 10.1006/jaut.1997.0131.PubMed
112.
Moritani M, Yoshimoto K, Ii S, Kondo M, Iwahana H, Yamaoka T, Sano T, Nakano N, Kikutani H, Itakura M: Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes: A gene therapy model of autoimmune diabetes. J Clin Invest. 1996, 98: 1851-1859. 10.1172/JCI118986.PubMedCentralPubMed
113.
Matsumoto Y, Sumiya E, Sugita T, Sekimizu K: An Invertebrate Hyperglycemic Model for the Identification of Anti-Diabetic Drugs. PLoS ONE. 2011, 6 (3): e18292-10.1371/journal.pone.0018292.PubMedCentralPubMed
114.
Higgins PB, Bastarrachea RA, Lopez-Alvarenga JC, Garcia-Forey M, Proffitt JM, Voruganti SV, Tejero ME, Mattern V, Haack K, Shade RE, Cole SA, Comuzzie AG: Eight week exposure to a high sugar high fat diet results in adiposity gain and alterations in metabolic biomarkers in baboons (Papio hamadryas sp.). Cardiovascular Diabetology. 2010, 9: 71-10.1186/1475-2840-9-71.PubMedCentralPubMed
Metadata
Title
Acute and chronic animal models for the evaluation of anti-diabetic agents
Authors
Suresh Kumar
Rajeshwar Singh
Neeru Vasudeva
Sunil Sharma
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-9

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue

Original investigation

Reduction of n-3 PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta-oxidation in type 2 diabetic rat heart

Original investigation

Insulin resistance and exercise tolerance in heart failure patients: linkage to coronary flow reserve and peripheral vascular function

Original investigation

Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study

Original investigation

Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes

Original investigation

The role of Na+/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db/db mice

Original investigation

High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits